Allergy Therapeutics plc - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 53

Allergy Therapeutics plc – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Allergy Therapeutics plc - Product Pipeline Review - H2 2011” provides data on the Allergy Therapeutics plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Allergy Therapeutics plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Allergy Therapeutics plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Allergy Therapeutics plc - Brief Allergy Therapeutics plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Allergy Therapeutics plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Allergy Therapeutics plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Allergy Therapeutics plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Allergy Therapeutics plc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Allergy Therapeutics plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Allergy Therapeutics plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Allergy Therapeutics plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Allergy Therapeutics plc and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Allergy Therapeutics plc; Allergy Therapeutics plc - Key Therapeutics; Allergy Therapeutics plc - Pipeline Overview and Promising Molecules; Allergy Therapeutics plc - News; Allergy Therapeutics plc - Latest Updates; Allergy Therapeutics plc - Pipeline; Allergy Therapeutics plc - Discontinued/Dormant Projects

List of Tables
List of Figures
Allergy Therapeutics plc Snapshot
Allergy Therapeutics plc Overview
Key Information
Key Facts
Allergy Therapeutics plc – Research and Development Overview
Key Therapeutic Areas
Allergy Therapeutics plc – Pipeline Review
Pipeline Products by Stage of Development
Allergy Therapeutics plc – Pipeline Products Glance
Allergy Therapeutics plc – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Allergy Therapeutics plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Allergy Therapeutics plc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Allergy Therapeutics plc – Drug Profiles
Pollinex Quattro Grass
Pollinex Quattro Japanese Cedar
Pollinex Quattro Ragweed
Pollinex Quattro Tree
Sublingual MPL
Allergy Therapeutics plc – Pipeline Analysis
Allergy Therapeutics plc – Pipeline Products by Therapeutic Class
Allergy Therapeutics plc – Pipeline Products by Route of Administration
Allergy Therapeutics plc - Dormant Projects
Allergy Therapeutics plc – Company Statement
Allergy Therapeutics plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Apr 28, 2006: Allergy Therapeutics Announces Positive Outcome For Its Key Clinical Efficacy And Safety Study Of Pollinex Quattro Ragweed
Apr 26, 2011: FDA To Lift Allergy Therapeutics INDs Clinical Hold For Three MATA-MPL Products
Oct 23, 2001: Allergy Presents Draft Report Of A Phase IIb Clinical Trial For Pollinex Quattro Tree Pollen Vaccine
Jul 23, 2009: Allergy Therapeutics Announces Granting Of European Patent For MPL-Based Sublingual Vaccines
Jul 23, 2009: European Patent Granted For MPL-Based Sublingual Vaccines
Jan 23, 2007: Allergy Therapeutics Announces Commencement Of Pollinex Quattro Grass Dosing In Phase III Trials
Sep 22, 2008: Allergy Therapeutics plc Announces Positive Results From Its Pollinex Quattro Ragweed Phase III Study
Jun 21, 2006: Allergy Therapeutics Announces Clinical Trial - R205 Update For Pollinex Quattro Ragweed
Jul 19, 2006: Allergy Therapeutics Announces Successful Review Meeting With Japan’s Pharmaceutical And Medical Devices Agency Japan For The Development Of Pollinex Quattro
Jun 14, 2007: Allergy Therapeutics Announces Initiation Of Pollinex Quattro Grass Phase III Trial
May 14, 2008: Allergy Therapeutics Announces Phase III Trial Result Of Pollinex Quattro Grass
May 14, 2008: Pivotal Phase III Pollinex Quattro grass study meets primary efficacy endpoint
Oct 13, 2006: Allergy Therapeutics Announces Completion Of Phase II Clinical Trials Of Pollinex Quattro Ragweed
Jun 08, 2011: Allergy Therapeutics Receives Report On Marketing Authorization Application For Pollinex Quattro From Paul Ehrlich Institute
Jun 07, 2010: New Efficacy Data Emphasize The Benefit Of Pollinex Quattro Grass
May 04, 2009: Allergy Therapeutics Announces Submission Of Pollinex Quattro Grass Dossier For European Union ('EU') Regulatory Review
Dec 03, 2004: Allergy Therapeutics Granted UK Patent For Sublingual Vaccine
Apr 02, 2007: Allergy Therapeutics plc Announces Initiation Of Pivotal Phase III Pollinex Quattro Ragweed Allergy Trial
Financial Deals Landscape
Allergy Therapeutics plc, Deals Summary
Allergy Therapeutics plc, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Allergy Therapeutics Enters Into Distribution Agreement With Lincoln Medical
Allergy Therapeutics Enters Into Distribution Agreement With Nycomed Canada
Allergy Therapeutics Enters Into Agreement With Allerpharma
Equity Offering
Allergy Therapeutics Completes Private Placement Of $3.36 Million
Allergy Therapeutics Completes Private Placement of $39 Million
Allergy Therapeutics Completes Private Placement Of $33 Million
Allergy Therapeutics Completes Private Placement Of $27 Million
Allergy Therapeutics Completes Initial Public Offering Of $28.8 Million
Acquisition
Allergy Therapeutics Completes Acquisition Of Teomed
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Allergy Therapeutics plc – Pipeline by Therapy Area and Indication, H2 2011
Allergy Therapeutics plc – Pipeline by Stage of Development, H2 2011
Allergy Therapeutics plc – Filed, H2 2011
Allergy Therapeutics plc – Phase III, H2 2011
Allergy Therapeutics plc - Phase II, H2 2011
Allergy Therapeutics plc - Phase I, H2 2011
Allergy Therapeutics plc - Pipeline By Therapeutic Class, H2 2011
Allergy Therapeutics plc – Pipeline By Route of Administration, H2 2011
Allergy Therapeutics plc - Dormant Developmental Projects, 2010
Allergy Therapeutics plc, Subsidiaries
Allergy Therapeutics plc, Deals Summary
Allergy Therapeutics Enters Into Distribution Agreement With Lincoln Medical
Allergy Therapeutics Enters Into Distribution Agreement With Nycomed Canada
Allergy Therapeutics Enters Into Agreement With Allerpharma
Allergy Therapeutics Completes Private Placement Of $3.36 Million
Allergy Therapeutics Completes Private Placement of $39 Million
Allergy Therapeutics Completes Private Placement Of $33 Million
Allergy Therapeutics Completes Private Placement Of $27 Million
Allergy Therapeutics Completes Initial Public Offering Of $28.8 Million
Allergy Therapeutics Completes Acquisition Of Teomed

List of Figures
Allergy Therapeutics plc – Pipeline by Therapy Area and Indication, H2 2011
Allergy Therapeutics plc – Pipeline by Stage of Development, H2 2011
Allergy Therapeutics plc – Pipeline By Therapeutic Class, H2 2011
Allergy Therapeutics plc – Pipeline By Route of Administration, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Ixia - Company Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Analysis of Google Inc
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Amazon - Point of Realization in 2013?
• Cisco - A Tenuous Turnaround